Program Description

Antimicrobial resistance poses a serious public health threat, with newly resistant pathogens emerging in both hospital and community settings. Numerous highly virulent bacteria have developed resistance to one or more classes of antibiotics. A critical need exists for new antibiotics that exhibit activity against resistant pathogens and have a low potential to induce resistance. New classes of antibiotics on the horizon are being developed specifically to treat moderate to serious infections caused by drug-resistant pathogens.

This session will address the growing threat of antibiotic resistance and its impact on the efficacy of current and future antimicrobial agents. The program will include discussion of the economic implications of appropriate management of infections caused by resistant pathogens with emphasis on moderate to severe infections. New and emerging therapeutic options for treating polymicrobial infections will be discussed with emphasis on opportunities for pharmacists to develop guidelines to ensure optimum clinical and economic outcomes for their patients.